
Opinion|Videos|April 3, 2023
Analyzing Phase 3 Clinical Trial Data of Baricitinib in Alopecia Areata
The expert panel discusses the secondary analysis from the phase 3 BRAVE clinical trials of baricitinib in alopecia areata.
Advertisement
Episodes in this series

Advertisement
Related to this article

End-of-study B-Well data show 91% of patients with chronic hepatitis B who achieved functional cure with bepirovirsen maintained it through Week 96.

With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.

Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).

Post hoc phase 2 data show survodutide improved MASH and fibrosis endpoints across all weight loss categories, including patients losing less than 5%.

Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).

Adding spironolactone lowered 3-month home SBP by 7.7 mm Hg vs standard care in 160 stroke survivors with uncontrolled hypertension.

A systolic target below 120 mm Hg lowered major cardiovascular events vs below 140 mm Hg in 4368 patients with prior ischemic stroke or TIA.
Advertisement
Advertisement
Trending on HCPLive
1
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
2
Cannabis Use Tied to Higher Odds of Stroke, Cardiovascular Disease
3
AHA 2026: Intensive Blood Pressure Control Reduces Events After Ischemic Stroke
4
STREAM: Statin Discontinuation Noninferior in Older Adults Without CVD
5




